Commons Sense

House of Commons · Written Ministerial Statement

Evaluation and Purchase of Antimicrobials

20 June 2022 · Department of Health and Social Care

Proposed by Sajid Javid Con Bromsgrove

NHSNorthern IrelandScotlandWales

Summarised by AI from the official record, so it can contain mistakes.

View on Parliament.uk

At a glance

Key points

  • The Secretary of State has signed contracts with NHS England and Improvement and two pharmaceutical companies, Shionogi and Pfizer, for a subscription-style payment model.
  • The contracts aim to incentivise pharmaceutical companies to develop new antimicrobials.
  • The Secretary of State will write to his counterparts in Scotland, Wales, and Northern Ireland to invite them to participate in the project.

Issue summary

The statement addresses the development and implementation of a new purchasing model for antibiotics to incentivise pharmaceutical companies to develop new antimicrobials.

Action requested

I have signed contracts between NHS England and Improvement (NHSEI) and two pharmaceutical companies, Shionogi and Pfizer, for a 'subscription-style' payment model. I will also write to my counterparts in Scotland, Wales, and Northern Ireland inviting them to participate in the next steps of this project.

Key facts

  • The Government has committed to develop a new purchasing model for antimicrobials that de-links payments from volumes used.
  • A joint project was launched by NHSEI, NICE, and DHSC in July 2019 to test a subscription-style payment for two antibiotics.
  • Payments for Cefiderocol (Shionogi) and Ceftazidime with Avibactam (Pfizer) will start on 1 July 2022.
  • The project is described as world-leading in incentivising innovation in antimicrobial drugs.
▸ Assessment & feedback
Summary accuracy